Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 28, 2023 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2022, and recent company...
February 24, 2023 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update

NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, February 28, 2023 at 8:30 AM ET to discuss results...
February 24, 2023 07:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™...
February 14, 2023 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials...
January 26, 2023 07:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis

NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of...
January 06, 2023 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 06, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 41st...
December 28, 2022 13:48 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)

BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms of multiple sclerosis that can be administered in a one-hour infusion twice-a-year following the...
November 10, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2022 and recent company developments,...
November 08, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Host Conference Call on Third Quarter 2022 Financial Results and Business Update

NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Thursday, November 10, 2022 at 8:30 AM ET to discuss results...
October 26, 2022 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis

NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory analyses from the ULTIMATE I & II Phase 3 trials...